Utilization of radiation therapy in multiple myeloma: trends and changes in practice
| Autor: | Asher Chanan-Khan, Aneel Paulus, David O. Hodge, Taimur Sher, Mark A. Fiala, Meghna Ailawadhi, Vivek Roy, Chander Shekher Aggarwal, Prachi Jani, Mays F Abdulazeez, Salman Ahmed, Victoria R. Alegria, Sonikpreet Aulakh, Ryan D. Frank, Sikander Ailawadhi, Zahara Kanji |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Databases Factual medicine.medical_treatment Medical Oncology Cohort Studies 03 medical and health sciences 0302 clinical medicine Healthcare delivery Patient age Internal medicine medicine Humans Initial treatment Practice Patterns Physicians' Multiple myeloma Aged Aged 80 and over Hematology business.industry Puerto Rico Cancer General Medicine Middle Aged medicine.disease United States Radiation therapy Socioeconomic Factors 030220 oncology & carcinogenesis Plasmacytoma Female Radiology Multiple Myeloma business 030215 immunology |
| Zdroj: | Annals of Hematology. 100:735-741 |
| ISSN: | 1432-0584 0939-5555 |
| Popis: | Plasma cell disorders including plasmacytomas and multiple myeloma (MM) are exquisitely radiosensitive, and thus, radiation therapy (XRT) is used effectively in their management. The role of XRT in the setting of novel MM therapeutics has not been explored. The 2016 National Cancer Database (NCDB) for MM with patients diagnosed between 2004 and 2013 was studied. Association between utilization of XRT as part of initial therapy and patient, disease, or treating facility characteristics was studied. A total of 111,281 cases with 91.6% MM, 7% osseous plasmacytoma (PLA-O), and 1.4% extramedullary plasmacytoma (PLA-E) were identified. XRT was utilized as part of initial therapy in 25.4% cases, including 69.3% of PLA-O, 60% of PLA-E, and 21.5% of MM patients. Patients with PLA-E and MM were significantly less likely to receive XRT as compared to PLA-O (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink